No Prescription |
 |
 | ||
|
Nordette |
|
| ||
No Prescription » Prescription Drugs 12 » Nordette Nordette is an oral contraceptive. Nordette tablets contain two hormones (levonorgestrel and ethinyloestradiol) which prevent you from becoming pregnant if taken correctly. They are similar to the hormones that your body normally produces. Nordette prevents pregnancy in several ways:#It inhibits the egg release by stopping it maturing #It changes the cervical mucus consistency making it difficult for the sperm to reach the egg #It changes the lining of the uterus making it less suitable for implantation. Your doctor may have prescribed Nordette for another reason. Ask your doctor if you have any questions about why Nordette has been prescribed for you. Nordette is not habit-forming. Buy Nordette and other Prescription Drugs 12 products online at Medstore. 5345
About Nordette: Product Type: Prescription Drugs 12 Nordette/Monofeme ( Ovral L Seasonale Microgynon Generic Levonorgestrel/Ethinyloestradiol ) Nordette/Monofeme (Ovral L Seasonale Microgynon Generic Levonorgestrel/Ethinyloestradiol) Ovral L Seasonale Microgynon Generic Levonorgestrel/Ethinyloestradiol 150/30mcg 3 x 28 Tablets Ovral L Seasonale Microgynon Generic Levonorgestrel/Ethinyloestradiol Nordette/Monofeme
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
